Harnessing the microbiome to restore immunotherapy response

被引：0

作者：

Susan Bullman

Alexander Eggermont

Christopher D. Johnston

Laurence Zitvogel

机构：

[1] Fred Hutchinson Cancer Research Center,Human Biology Division

[2] University Medical Center Utrecht,Clinical&Translational Immunotherapy

[3] Princess Máxima Center for pediatric oncology,Vaccine and Infectious Disease Division

[4] Fred Hutchinson Cancer Research Center,Faculty of Medicine

[5] Université Paris Saclay,undefined

[6] INSERM,undefined

[7] Equipe labellisée Ligue Contre le Cancer,undefined

[8] Center of Clinical Investigations in Biotherapies of Cancer BIOTHERIS,undefined

来源：

Nature Cancer | 2021年 / 2卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Despite the profound clinical success of immune-checkpoint inhibitors, their effectiveness is limited by intrinsic and acquired resistance. Bullman, Zitvogel and colleagues provide their views on two clinical trials modulating the microbiome of immunotherapy-resistant patients with melanoma via transplantation of fecal microbiota from patients who responded to immunotherapy.

引用

页码：1301 / 1304

页数：3

共 13 条

[1]

Vetizou M(2015)undefined Science 350 1079-1084

[2]

Sivan A(2015)undefined Science 350 1084-1089

[3]

Routy B(2018)undefined Science 359 91-97

[4]

Gopalakrishnan V(2018)undefined Science 359 97-103

[5]

Matson V(2018)undefined Science 359 104-108

[6]

Baruch EN(2021)undefined Science 371 602-609

[7]

Davar D(2021)undefined Science 371 595-602

[8]

Tanoue T(2019)undefined Nature 565 600-605

[9]

Derosa L(2021)undefined Cancer Discov. 11 2396-2412

[10]

van Nood E(2013)undefined N. Engl. J. Med. 368 407-415

← 1 2 →